Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 19/20 | 0.71 |
| ▸ | HTR1D | P28221 | 15/20 | 0.71 |
| ▸ | HTR1B | P28222 | 15/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.71 |
| ▸ | DRD2 | P14416 | 4/20 | 0.59 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182150 | 0.87 | HTR1A (0.75) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| Hydrochloric Acid SCHEMBL4180926 | 0.86 | HTR1A (0.73) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL2300457 | 0.84 | HTR1A (0.59) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4182255 | 0.84 | HTR1A (0.68) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4170602 | 0.83 | HTR1A (1.00) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| Hydrochloric Acid SCHEMBL4180133 | 0.82 | HTR1A (0.98) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL2304001 | 0.82 | HTR1A (0.65) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL2302815 | 0.80 | HTR1A (0.61) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4179832 | 0.80 | HTR1A (0.63) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL2303687 | 0.79 | HTR1A (0.53) | HTR1AHTR1DHTR1BSLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | claimed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | HTR1A 47/4885HTR1D 75/4885HTR1B 39/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | HTR1A 476/4885HTR1D 569/4885HTR1B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.